Legend Biotech Corporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 16.88 million compared to USD 11.75 million a year ago. Net loss was USD 124.75 million compared to USD 66.55 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 0.5 a year ago. Diluted loss per share from continuing operations was USD 0.86 compared to USD 0.5 a year ago. For the nine months, sales was USD 50.8 million compared to USD 34.89 million a year ago. Net loss was USD 297.88 million compared to USD 245.65 million a year ago. Basic loss per share from continuing operations was USD 2.14 compared to USD 2.16 a year ago. Diluted loss per share from continuing operations was USD 2.14 compared to USD 2.16 a year ago.